CLEC9A and Miyoshi myopathy: The concept that CLEC9A+ conventional type1 DCs (cDC1s) may serve as APCs for activation of T cells in situ in MM is also consistent with their role as a DC subset specialized for cross-presentation (27) and with the data correlating these cells with response to immune therapies in solid tumors (28, 29).